Prognostic significance of Memorial Sloan–Kettering prognostic score in small-cell lung cancer patients-Reference-Cited by-同舟云学术

Prognostic significance of Memorial Sloan–Kettering prognostic score in small-cell lung cancer patients

Published:2023-04 Issue:7 Volume:17 Page:391-401
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Chen Shuangqing¹²,Liu Shicheng¹,Kong Lingxin¹³,Ren Dahu¹³,Hu Zhonghui¹,Wu Wenbo¹,Duan Guochen¹⁴^ORCID

Affiliation:

1. Department of Thoracic Surgery, Hebei General Hospital, Shijiazhuang, 050057, People’s Republic of China

2. Graduate School, Hebei North University, Zhangjiakou, 075000, People’s Republic of China

3. Graduate School, Hebei Medical University, Shijiazhuang, 050011, People’s Republic of China

4. Department of Thoracic Surgery, Children’s Hospital of Hebei Province, Shijiazhuang, 050000, People’s Republic of China

Abstract

Aim: To assess the potential factors with predictive value for survival in small-cell lung cancer (SCLC) patients and to develop a nomogram prediction model. Patients & methods: We retrospectively screened and analyzed patients with pathologically confirmed SCLC from April 2015 to December 2021. Results: A total of 167 patients with SCLC were included. According to the Memorial Sloan–Kettering prognostic score (MPS), patients were divided into three groups: group 0 (n = 65), group 1 (n = 69) and group 2 (n = 33). The multivariate analysis showed that MPS was an independent prognostic factor for progression-free and overall survival in SCLC patients (p < 0.05). The nomogram showed that MPS was the most influential factor for overall survival. Conclusion: MPS is an independent prognostic factor for overall and progression-free survival in SCLC patients and performed better than other indicators used in this study.

Funder

Hebei Provincial Key Research Projects

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2023-0105

Reference30 articles.

1. Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches

Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades

3. Small cell lung cancer enters the era of precision medicine

4. Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

5. Naples Prognostic Score is an Independent Prognostic Factor in Patients with Small Cell Lung Cancer and Nomogram Predictive Model Established